Skip to main content
. Author manuscript; available in PMC: 2015 Mar 5.
Published in final edited form as: Urol Oncol. 2013 Aug 2;32(1):43.e23–43.e30. doi: 10.1016/j.urolonc.2013.05.008

Fig. 5.

Fig. 5

TSGs responded to sunitinib treatment. Control TSGs generated from case 1 showed good vascularization, (A) compared with TSGs treated with sunitinib, (B) Treated TSGs had significantly lower graft weights compared with control TSGs, (C) Blood vessels lined by human endothelial cells were readily observed in control TSGs (arrows in D), whereas empty spaces in the shape of blood vessels were seen in treated TSGs (arrow in E). The mean vessel intensity in 10 high-power fields in control TSGs was significantly higher than that in treated TSGs, (F). (Color version of the figure is available online.)